Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at stereotactic body radiotherapy before surgery for pancreatic cancer (SPARC)
This trial is looking at different doses of stereotactic body radiotherapy (SBRT) to shrink pancreatic cancer before surgery. It is for people whose pancreatic cancer could possibly be removed with surgery, but the operation may be difficult. This trial is supported by Cancer Research UK.
More about this trial
If pancreatic cancer is diagnosed at an earlier stage it may be possible to have surgery to remove it. But some people have a cancer that is very close to the large blood vessels, so the operation may not be possible or it may not be straightforward to do.
Researchers are trying to find out if a type of radiotherapy called stereotactic body radiotherapy (SBRT) could shrink the cancer and reduce the risk of any cancer being left behind.
SBRT directs radiotherapy beams at the cancer from different positions around the body. It accurately delivers a high dose of treatment to the cancer while the surrounding tissue only receives a low dose.
The aims of this trial are to
- Find the best and safest dose of SBRT
- See whether SBRT before surgery improves the chances of removing all the pancreatic cancer
- Learn more about the side effects of SBRT
Who can enter
You may be able to join this trial if all of the following apply. You
- Have pancreatic cancer and your specialist thinks it may be possible to remove it with surgery, but there is a high risk of cancer being left
- Are fit and well enough to have surgery (you have a performance status of 0 or 1)
- Are fit and well enough to have biliary drainage using a stent if you have a blockage in your bile duct
- Have satisfactory blood test results
- Are at least 16 years old
You cannot join this trial if any of these apply. You
- Have cancer in the tail of your pancreas
- Have pancreatic cancer that has grown into surrounding tissues unless this can be included in the area that is treated with radiotherapy
- Have pancreatic cancer that has spread elsewhere in your body
- Have already had radiotherapy to the upper part of your stomach or the right side of your chest, where 30% of the liver had had a dose of more than 15 Grey
- Have a cancer that is more of a risk to your health than your current diagnosis of pancreatic cancer. You can still take part if you have had a very early stage cancer that has been successfully treated and has not come back in the last 3 years . For example, localised prostate cancer, early stage colorectal cancer or carcinoma in situ of the cervix
- Have any other serious medical condition or mental health problem that the trial team think could affect you taking part
- Are pregnant or breast feeding
This is a phase 1 trial. The researchers need up to 24 people to join.
The first few patients taking part will have a low dose of stereotactic body radiotherapy (SBRT). If they don’t have any serious side effects, the next few patients will have a higher dose. And so on, until they find the best dose to give. This is called a dose escalation study. You will be told what dose you are having. The researchers aim to test up to 4 different doses of SBRT.
You have 5 treatments of SBRT over 5 to 8 days. You have scans during your radiotherapy treatments to make sure that the SBRT is as accurate as possible. For example, the position of your cancer or other parts of the body such as the bowel might move slightly. If this happens, the treatment position will need to be adjusted. This is called image guided radiotherapy.
Each treatment session takes about 30 to 45 minutes. The radiotherapy treatment itself only takes a few minutes. The rest of the time is used to get you in the right position, take scans and move the machine around your body to deliver treatment from different angles.
You see a member of the trial team once during your 5 to 8 days of treatment. They will ask you about side effects and suggest ways to manage the side effects if possible.
A few weeks after you finish SBRT, your doctor will assess you to decide whether you can now have an operation to remove your cancer. If you have surgery, this will take place about 5 to 6 weeks after finishing SBRT.
You have some tests to help the trial doctor decide whether you can take part in this trial. These tests include
- Blood tests
- Physical examination
- CT scan if you haven’t had one in the last month
These scans help to show exactly where the cancer is. This information is entered into a computer that the doctors use to create your treatment plan.
You have 3 or 4 small permanent marks put on the skin of your stomach and side (a bit like a very small tattoo). These help the
Your radiotherapy planning involves 1 or 2 hospital visits and each appointment takes about 40 minutes.
You have a CT scan about 4 weeks after finishing SBRT to see if the treatment has worked.
If you are able to have surgery you will stay in hospital for about 10 to 14 days although this may vary from one person to another.
You visit hospital to see the trial doctor 3 months and 6 months after your radiotherapy has finished. All further appointments will then be part of your routine care, depending on what treatment or support you have.
The trial team will find out how you are doing 1 and 2 years later. They do this by contacting your doctor and looking at your medical records.
You will not feel anything during stereotactic body radiotherapy (SBRT), it is a bit like having an X-ray or a scan.
The most common side effect of SBRT are
- Tiredness (fatigue)
- Sore skin in the treatment area (this may only be mild)
- Feeling or being sick (you will be given anti sickness tablets)
There are other possible side effects that are not as common, the trial team will discuss these with you.
How to join a clinical trial
Professor Maria A. Hawkins
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
Cancer Research UK Oxford Centre
CRUK/MRC Oxford Institute for Radiation Oncology
Oncology Clinical Trials Office (OCTO)
Oxford Clinical Trials Research Unit (OCTRU)
University of Oxford
National Institute for Health Research (NIHR)